Abstract
In 2008, the combined European biomaterial market was worth €271.4
million. This includes hyaluronic acid viscosupplements, bone graft
substitutes, BMP growth factors, autologous chondrocyte implantation and
platelet/bone marrow concentration systems. Within this report, the various
bone grafting materials are examined, including autografted bone, allografts,
demineralized bone and synthetic bone substitutes. The market across Europe is
highly dependant on regulation, reimbursement and regional supply issues. Each
of these has shaped the products of preference in each country, and
understanding how they interact is a vital importance in providing orthopedic
biomaterials to the European market. The European market encompasses Germany,
France, Italy, United Kingdom (U.K.), Spain, Benelux (Belgium, the
Netherlands, and Luxemburg), Scandinavia (Finland, Denmark, Sweden and
Norway), Switzerland, Austria, and Portugal.
| 
View Cart
